8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 5, 2026·SEC
Caribou Biosciences, Inc.(CRBU)Earnings, Financials & Key Ratios
CRBU•NASDAQ
Price updated Jun 19, 2026
AboutCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.Show more
- Revenue$11M+11.7%
- EBITDA-$133M+18.5%
- Net Income-$148M+0.7%
- EPS (Diluted)-1.59+3.6%
- Gross Margin67.34%+10.9%
- EBITDA Margin-1187.82%+27.0%
- Operating Margin-1220.49%+26.8%
- Net Margin-1327.4%+11.0%
- ROE-78.97%-64.5%
CRBU Key Insights
Caribou Biosciences, Inc. (CRBU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Profits declining 34.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CRBU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CRBU Price & Volume
Caribou Biosciences, Inc. (CRBU) stock price & volume — 10-year historical chart
Loading chart...
CRBU Growth Metrics
Caribou Biosciences, Inc. (CRBU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-2.03%
3 Years-6.95%
TTM12.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM12.35%
Return on Capital
10 Years-51.81%
5 Years-40.16%
3 Years-47.49%
Last Year-62.96%
CRBU Recent Earnings
Caribou Biosciences, Inc. (CRBU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.26+21.2%
$0.33
Rev
$2M+8.3%
$2M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.28+15.2%
$0.33
Rev
$4M+78.6%
$2M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.30+16.7%
$0.36
Rev
$2M+12.3%
$2M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.35+12.5%
$0.40
Rev
$3M+74.1%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.26vs $0.33+21.2% | $2Mvs $2M+8.3% |
| Q2 2026 | Mar 5, 2026 | $0.28vs $0.33+15.2% | $4Mvs $2M+78.6% |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.36+16.7% | $2Mvs $2M+12.3% |
| Q3 2025 | Aug 12, 2025 | $0.35vs $0.40+12.5% | $3Mvs $2M+74.1% |
Based on last 12 quarters of dataView full earnings history →
CRBU Peer Comparison
Caribou Biosciences, Inc. (CRBU) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare CRBU vs Peers
Caribou Biosciences, Inc. (CRBU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRBU Income Statement
Caribou Biosciences, Inc. (CRBU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 5.79M | 12.36M | 9.6M | 13.85M | 34.48M | 9.99M | 11.16M | 11.2M |
Revenue Growth % | - | 113.56% | -22.35% | 44.31% | 148.91% | -71.01% | 11.66% | 12.96% |
Cost of Goods Sold | 0 | 34.42M | 984K | 3.64M | 3.52M | 3.93M | 3.65M | 649K |
COGS % of Revenue | - | 278.5% | 10.25% | 26.29% | 10.22% | 39.29% | 32.66% | - |
Gross Profit | 5.79M▲ 0% | -22.06M▼ 481.2% | 8.61M▲ 139.0% | 10.21M▲ 18.5% | 30.95M▲ 203.2% | 6.07M▼ 80.4% | 7.51M▲ 23.9% | 10.55M▲ 0% |
Gross Margin % | 100% | -178.5% | 89.75% | 73.71% | 89.78% | 60.71% | 67.34% | 94.21% |
Gross Profit Growth % | - | -481.2% | 139.04% | 18.53% | 203.15% | -80.4% | 23.85% | - |
Operating Expenses | 40.09M | 14.06M | 75.59M | 116.61M | 147.01M | 172.68M | 143.71M | 142.26M |
OpEx % of Revenue | 692.69% | 113.74% | 787.59% | 841.88% | 426.4% | 1727.87% | 1287.82% | - |
Selling, General & Admin | 16.46M | 14.06M | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M | 36.24M |
SG&A % of Revenue | 284.35% | 113.74% | 243.15% | 274.49% | 111.56% | 464.85% | 339.76% | - |
Research & Development | 23.64M | 34.42M | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M | 94.52M |
R&D % of Revenue | 408.34% | 278.5% | 544.44% | 593.68% | 325.07% | 1302.31% | 980.72% | - |
Other Operating Expenses | 0 | -34.42M | 0 | -3.64M | -3.52M | -3.93M | -3.65M | 351K |
Operating Income | -34.3M▲ 0% | -36.12M▼ 5.3% | -66.98M▼ 85.4% | -106.4M▼ 58.9% | -116.06M▼ 9.1% | -166.62M▼ 43.6% | -136.19M▲ 18.3% | -131.71M▲ 0% |
Operating Margin % | -592.69% | -292.24% | -697.84% | -768.17% | -336.63% | -1667.16% | -1220.49% | -1175.68% |
Operating Income Growth % | - | -5.3% | -85.41% | -58.85% | -9.08% | -43.56% | 18.26% | - |
EBITDA | -33.55M | -35.22M | -66M | -102.76M | -112.53M | -162.69M | -132.55M | -128.58M |
EBITDA Margin % | -579.72% | -284.96% | -687.59% | -741.88% | -326.4% | -1627.87% | -1187.82% | -1147.75% |
EBITDA Growth % | - | -4.98% | -87.36% | -55.71% | -9.51% | -44.57% | 18.53% | 19.2% |
D&A (Non-Cash Add-back) | 751K | 900K | 984K | 3.64M | 3.52M | 3.93M | 3.65M | 3.13M |
EBIT | -30.96M | -36.11M | -66.59M | -99.35M | -116.06M | -166.62M | -136.19M | -119.56M |
Net Interest Income | 1.04M | 216K | 140K | 4.6M | 10.7M | 0 | 8M | 0 |
Interest Income | 1.05M | 236K | 148K | 4.6M | 10.7M | 0 | 8M | 0 |
Interest Expense | 4K | 20K | 8K | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 3.34M | -3K | 377K | 7.05M | 14.18M | 17.5M | -12.48M | -2.06M |
Pretax Income | -30.97M▲ 0% | -36.13M▼ 16.7% | -66.6M▼ 84.4% | -99.35M▼ 49.2% | -101.88M▼ 2.5% | -149.11M▼ 46.4% | -148.68M▲ 0.3% | -133.77M▲ 0% |
Pretax Margin % | -535.04% | -292.27% | -693.92% | -717.28% | -295.49% | -1492.04% | -1332.33% | -1194.05% |
Income Tax | -7.54M | -1.82M | 321K | 70K | 193K | -9K | -550K | -550K |
Effective Tax Rate % | 24.34% | 5.04% | -0.48% | -0.07% | -0.19% | 0.01% | 0.37% | 0.41% |
Net Income | -23.43M▲ 0% | -34.31M▼ 46.4% | -66.92M▼ 95.1% | -99.42M▼ 48.6% | -102.07M▼ 2.7% | -149.1M▼ 46.1% | -148.13M▲ 0.7% | -133.22M▲ 0% |
Net Margin % | -404.82% | -277.55% | -697.26% | -717.79% | -296.05% | -1491.95% | -1327.4% | -1189.14% |
Net Income Growth % | - | -46.42% | -95.07% | -48.56% | -2.66% | -46.08% | 0.66% | 9.9% |
Net Income (Continuing) | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M | -148.13M | -133.22M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.85▲ 0% | -1.24▼ 45.9% | -1.11▲ 10.5% | -1.64▼ 47.7% | -1.38▲ 15.9% | -1.65▼ 19.6% | -1.59▲ 3.6% | -1.39▲ 0% |
EPS Growth % | - | -45.88% | 10.48% | -47.75% | 15.85% | -19.57% | 3.64% | 12.35% |
EPS (Basic) | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 | -1.59 | - |
Diluted Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M | 95.86M |
Basic Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M | 95.86M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CRBU Balance Sheet
Caribou Biosciences, Inc. (CRBU) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 57.01M | 24.31M | 391.19M | 260.25M | 338.84M | 219.38M | 145.23M | 122.38M |
Cash & Short-Term Investments | 49.47M | 15.95M | 375.83M | 247.66M | 328.83M | 209.54M | 139.34M | 117.63M |
Cash Only | 41.07M | 15.95M | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M | 12.06M |
Short-Term Investments | 8.4M | 0 | 135.41M | 189.32M | 277.67M | 193.24M | 126.98M | 105.57M |
Accounts Receivable | 3.98M | 5.16M | 8.12M | 4.66M | 3.86M | 3.25M | 2.98M | 2.36M |
Days Sales Outstanding | 251.11 | 152.37 | 308.95 | 122.91 | 40.85 | 118.73 | 97.44 | 83.02 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 373K | 423K | 671K | 1.12M | 1.22M | 1.78M | 2.91M | 2.39M |
Total Non-Current Assets | 4.92M | 11.74M | 51.16M | 113.52M | 93.37M | 93.94M | 30.14M | 26.62M |
Property, Plant & Equipment | 4.33M | 3.5M | 4.89M | 34.91M | 40.45M | 39.29M | 24.43M | 23.48M |
Fixed Asset Turnover | 1.34x | 3.53x | 1.96x | 0.40x | 0.85x | 0.25x | 0.46x | 0.47x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 7.63M | 45.3M | 77.07M | 51.33M | 49.13M | 3.55M | 4.83M |
Other Non-Current Assets | 593K | 612K | 975K | 1.54M | 1.59M | 5.52M | 2.15M | 2.14M |
Total Assets | 61.93M▲ 0% | 36.05M▼ 41.8% | 442.36M▲ 1127.2% | 373.76M▼ 15.5% | 432.21M▲ 15.6% | 313.31M▼ 27.5% | 175.37M▼ 44.0% | 149M▲ 0% |
Asset Turnover | 0.09x | 0.34x | 0.02x | 0.04x | 0.08x | 0.03x | 0.06x | 0.06x |
Asset Growth % | - | -41.8% | 1127.2% | -15.51% | 15.64% | -27.51% | -44.03% | -172.36% |
Total Current Liabilities | 10.08M | 12.39M | 25.83M | 28.13M | 28.3M | 30.65M | 25.41M | 19.67M |
Accounts Payable | 2.54M | 2.6M | 3.99M | 1.15M | 3.12M | 2.48M | 5.78M | 3.5M |
Days Payables Outstanding | - | 27.58 | 1.48K | 114.88 | 323.06 | 230.13 | 579.09 | 2.3K |
Short-Term Debt | 532K | 654K | 259K | 0 | 0 | 0 | 0 | 1.29M |
Deferred Revenue (Current) | 717K | 161K | 8.7M | 9.94M | 2.85M | 3.13M | 1.9M | 7.93M |
Other Current Liabilities | 496K | 629K | 4.75M | 7.12M | 10.62M | 10.22M | 16.54M | 10.18M |
Current Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x | 5.71x | 6.22x |
Quick Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x | 5.71x | 6.22x |
Cash Conversion Cycle | - | - | - | - | - | - | - | -2.21K |
Total Non-Current Liabilities | 44.39M | 47.09M | 28.7M | 44.77M | 35.51M | 29.71M | 27.78M | 27.31M |
Long-Term Debt | 0 | 924K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 26.78M | 25.91M | 25.06M | 26.03M | 98.03M |
Deferred Tax Liabilities | 650K | 155K | 476K | 381K | 557K | 548K | 4.26M | 5.36M |
Other Non-Current Liabilities | 42.76M | 45.08M | 6.19M | 1.65M | 2.94M | 785K | -4.26M | 0 |
Total Liabilities | 54.47M | 59.48M | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M | 46.98M |
Total Debt | 532K | 1.58M | 259K | 27.75M | 27.11M | 26.49M | 27.23M | 26.95M |
Net Debt | -40.54M | -14.38M | -240.42M | -30.59M | -24.05M | 10.19M | 14.87M | 14.89M |
Debt / Equity | 0.07x | - | 0.00x | 0.09x | 0.07x | 0.10x | 0.22x | 0.26x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.21x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.12x |
Interest Coverage | -7741.00x | -1805.35x | -8324.25x | - | - | - | - | - |
Total Equity | 7.46M▲ 0% | -23.44M▼ 414.0% | 387.82M▲ 1754.8% | 300.87M▼ 22.4% | 368.4M▲ 22.4% | 252.95M▼ 31.3% | 122.17M▼ 51.7% | 102.02M▲ 0% |
Equity Growth % | - | -414.04% | 1754.76% | -22.42% | 22.44% | -31.34% | -51.7% | -200.78% |
Book Value per Share | 0.27 | -0.85 | 6.44 | 4.95 | 4.99 | 2.80 | 1.31 | 1.06 |
Total Shareholders' Equity | 7.46M | -23.44M | 387.82M | 300.87M | 368.4M | 252.95M | 122.17M | 102.02M |
Common Stock | 1K | 1K | 6K | 6K | 8K | 9K | 9K | 10K |
Retained Earnings | 3.44M | -30.87M | -97.79M | -197.22M | -299.29M | -448.39M | -596.51M | -621.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -135K | -1.52M | 30K | 255K | 103K | -23K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRBU Cash Flow Statement
Caribou Biosciences, Inc. (CRBU) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -32.01M | -33.22M | -32.52M | -90.97M | -93.29M | -138.2M | -110.99M | -101.25M |
Operating CF Margin % | -552.97% | -268.71% | -338.81% | -656.75% | -270.59% | -1382.83% | -994.64% | - |
Operating CF Growth % | - | -3.78% | 2.1% | -179.73% | -2.56% | -48.14% | 19.69% | 104.73% |
Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M | -148.13M | -133.22M |
Depreciation & Amortization | 751K | 900K | 984K | 3.64M | 3.52M | 3.93M | 3.65M | 3.13M |
Stock-Based Compensation | 1.23M | 1M | 3.45M | 0 | 13.75M | 16.71M | 12.68M | 8.42M |
Deferred Taxes | 0 | 0 | 0 | -95K | 0 | 0 | -548K | 0 |
Other Non-Cash Items | -2.29M | -986K | 904K | 9.02M | -1.18M | -4.61M | 21.84M | 24.36M |
Working Capital Changes | -8.27M | 177K | 29.07M | -4.11M | -7.32M | -5.11M | -484K | -3.94M |
Change in Receivables | -1.09M | -1.18M | -2.96M | 3.46M | 805K | 608K | 272K | 378K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.18M | 43K | 1.14M | -2.72M | 1.82M | -354K | 3.25M | -370K |
Cash from Investing | 27.23M | 6.36M | -176.4M | -93.25M | -68.18M | 86.61M | 102.24M | 76.84M |
Capital Expenditures | -884K | -317K | -2.12M | -6.45M | -11.61M | -4.88M | -1.36M | -389K |
CapEx % of Revenue | 15.27% | 2.56% | 22.1% | 46.6% | 33.68% | 48.83% | 12.18% | 3.47% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | -988K | -1M | -600K | 0 | -1.61M | 1.14M | 269K |
Cash from Financing | 172K | 1.74M | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M | 7.05M |
Debt Issued (Net) | -45K | 1.47M | 1.03M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 217K | 270K | 429.85M | 2.13M | 152.72M | 15.19M | 4.82M | 7.51M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 2.55M | 0 | 1.58M | 1.53M | 0 | -462K |
Net Change in Cash | -4.6M▲ 0% | -25.12M▼ 445.9% | 224.51M▲ 993.9% | -182.08M▼ 181.1% | -7.18M▲ 96.1% | -34.87M▼ 385.9% | -3.93M▲ 88.7% | -17.36M▲ 0% |
Free Cash Flow | -32.89M▲ 0% | -34.53M▼ 5.0% | -35.64M▼ 3.2% | -97.42M▼ 173.3% | -104.9M▼ 7.7% | -144.71M▼ 37.9% | -112.35M▲ 22.4% | -101.64M▲ 0% |
FCF Margin % | -568.24% | -279.35% | -371.33% | -703.34% | -304.27% | -1447.92% | -1006.82% | -907.26% |
FCF Growth % | - | -4.99% | -3.21% | -173.34% | -7.68% | -37.94% | 22.36% | 28.58% |
FCF per Share | -1.19 | -1.25 | -0.59 | -1.60 | -1.42 | -1.60 | -1.20 | -1.06 |
FCF Conversion (FCF/Net Income) | 1.37x | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x | 0.75x | 0.76x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 1.81M | 21K | 11K | 0 | 170K | 0 | 0 | 0 |
CRBU Key Ratios
Caribou Biosciences, Inc. (CRBU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -36.73% | -28.87% | -30.5% | -47.99% | -78.97% | -100.13% |
Return on Invested Capital (ROIC) | - | -91.46% | -38.19% | -28.32% | -41.14% | -51.05% | -68.49% |
Gross Margin | -178.5% | 89.75% | 73.71% | 89.78% | 60.71% | 67.34% | 94.21% |
Net Margin | -277.55% | -697.26% | -717.79% | -296.05% | -1491.95% | -1327.4% | -1189.14% |
Debt / Equity | - | 0.00x | 0.09x | 0.07x | 0.10x | 0.22x | 0.26x |
Interest Coverage | -1805.35x | -8324.25x | - | - | - | - | - |
FCF Conversion | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x | 0.75x | 0.76x |
Revenue Growth | 113.56% | -22.35% | 44.31% | 148.91% | -71.01% | 11.66% | 12.96% |
Related:CRBU Dividend History·CRBU Revenue History·CRBU Price History·CRBU P/E History·CRBU Financial Ratios·CRBU Institutional Holders
CRBU SEC Filings & Documents
Caribou Biosciences, Inc. (CRBU) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRBU Frequently Asked Questions
Caribou Biosciences, Inc. (CRBU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Caribou Biosciences, Inc. (CRBU) reported $11.2M in revenue for fiscal year 2025. This represents a 94% increase from $5.8M in 2019.
Caribou Biosciences, Inc. (CRBU) grew revenue by 11.7% over the past year. This is steady growth.
Caribou Biosciences, Inc. (CRBU) reported a net loss of $133.2M for fiscal year 2025.
Dividend & Returns
Caribou Biosciences, Inc. (CRBU) has a return on equity (ROE) of -79.0%. Negative ROE indicates the company is unprofitable.
Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $101.6M in fiscal year 2025, likely due to heavy capital investments.